Epigenetic enhancement of adoptive T cell immunotherapy
Cancer Cell · 2025
DOI: 10.1016/j.ccell.2025.02.022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2025. Verfasst von Zhenyu Dai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, T-Lymphocytes, Epigenesis, Genetic, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Gefördert von: Stanford University.
Abstract (Originalsprache)
Isshiki et al. and Porazzi et al. report that inhibiting enhancer of zeste homolog 1 (EZH1) and EZH2 enhances chimeric antigen receptor (CAR)/T cell receptor (TCR)-based therapies by reprogramming tumors to be more immunogenic and improving T cell phenotype and demonstrate the efficacy of this combination in preclinical models across hematologic and solid cancers. Clinical trials are ongoing to evaluate its safety and therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
- Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: melodysm@stanford.edu.
Förderung
- Stanford University
Zitieren
APA
Dai, Z., & Smith, M. (2025). Epigenetic enhancement of adoptive T cell immunotherapy. Cancer Cell. https://doi.org/10.1016/j.ccell.2025.02.022
Vancouver
Dai Z, Smith M. Epigenetic enhancement of adoptive T cell immunotherapy. Cancer Cell. 2025. doi:10.1016/j.ccell.2025.02.022
BibTeX
@article{Dai2025,
author = {Dai, Zhenyu and Smith, Melody},
title = {Epigenetic enhancement of adoptive T cell immunotherapy},
journal = {Cancer Cell},
year = {2025},
doi = {10.1016/j.ccell.2025.02.022}
}
EUVIMED